# An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

> **NCT01019161** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** AZD1152
- **DRUG:** C14 AZD1152

## Key facts

- **NCT ID:** NCT01019161
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2010-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019161, "An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01019161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*